NEW YORK, July 25, 2017 /PRNewswire/ -- The biologics safety testing market was valued at USD 2.75 billion in 2017 and expected to grow at a CAGR of 12.2% to a USD 4.90 billion market by 2022. Growth in pharmaceutical and biotechnology industry driven by government support, the positive trend of R&D investment in the life science industry, and an increase in the number of new drug launches are factors driving the growth of this market. On the other hand, the time-consuming approval process for new drugs is considered a restraint for the market.Read the full report: http://www.reportlinker.com/p05018003/Biologics-Safety-Testing-Market-by-Product-Test-Application-Global-Forecast-to.html"Kits & reagents segment is expected to register the highest CAGR during the forecast period"The biologics safety testing market is classified on the basis of product & service into kits & reagents, services, and instruments. The kits & reagents segment is expected to register highest growth rate during the forecast period. This growth can be attributed to the reoccurring purchase of kits & reagents, which is required for running tests."Endotoxin tests segment is accounted for largest share in the market"The biologics safety testing market is classified by test type into endotoxin tests, sterility tests, cell line authentification and characterization tests, residual host contamination detection tests, adventitious agent detection tests, bioburden tests, and other tests. The endotoxin tests segment is expected to register the highest growth rate during the forecast period. This growth can be attributed to the increase in the number of drug launches."Increase initiative for immunization, increase company investment in vaccines development drives growth of the vaccines and therapeutics development segment"By application, the biologics safety testing market is segmented into vaccine and therapeutics development; blood and blood-related products testing; cellular and gene therapy; tissue and tissue-related products testing; and stem cell research. The vaccine and therapeutics development segment are expected to register highest CAGR during the forecast period. The growth in this segment primarily attributed to initiatives for immunization and increased company investment in the development of vaccines."North America is account for the largest regional segment in the market"Geographically, the biologics safety testing market is dominated by North America, followed by Europe. The North American region is estimated to account for the largest share of the market in 2017 and the trend is expected to continue during the forecast period. The growth in this market can be attributed to the presence of major key players in the region, a strong trend in R&D in life science industry and an increase in drug approvals. The primary interviews conducted for this report can be categorized as follows:• By Company Type - Tier 1 – 43%, Tier 2 – 14% and Tier 3 – 43%• By Designation – C level – 14%, Director level – 43%, Others – 43% • By Region – North America - 29%, Europe – 14%, APAC – 43%, RoW – 14% Key players operating in the biologics safety testing market include Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany), SGS SA (Switzerland), WuXi Apptec (China), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Cytovance Biologics, Inc. (U.S.), Pace Analytical Services Inc. (U.S.), and Toxikon Corporation (U.S.).Study Coverage:The report analyses the biologics safety testing market by product & service, test type, applications, and regions. Apart from comprehensive geographic and product & service analysis and market sizing, the report also provides the competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the report profiles companies with developments, and strategies adopted by key players to maintain and increase their shares in the market. The market research data, market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions to be successful in the market. Benefits of Buying this Report:This report will enable both established firms as well as new entrants/smaller firms gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the five strategies mentioned below to strengthen their market shares.The report provides insights on the following strategies:• Market Penetration: The report analyzes the biologics safety testing market by product & service, test type and application• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the biologics safety testing market• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biologics safety testing product & service across geographies • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the biologics safety testing market Read the full report: http://www.reportlinker.com/p05018003/Biologics-Safety-Testing-Market-by-Product-Test-Application-Global-Forecast-to.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/biologics-safety-testing-market-by-product-test-application---global-forecast-to-2022-300494100.html
SOURCE Reportlinker
